On November 19, 2020 Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed/refractory multiple myeloma (R/R MM) at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held virtually Dec. 5-8, 2020 (Press release, TeneoBio, NOV 19, 2020, View Source;utm_medium=rss&utm_campaign=tnb-383b-anti-bcmaxcd3 [SID1234571421]). TNB-383B is a fully human bispecific antibody that targets BCMA on the surface of multiple myeloma (MM) cells and CD3 on the surface of T cells in order to trigger lysis of MM cells in R/R MM patients. The open-label multi-center trial is designed to assess the safety, pharmacokinetics and preliminary efficacy of TNB-383B administered intravenously once every 21 days.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The interim results will be presented on Saturday Dec. 5 at 2:45 pm PT in an oral presentation by Cesar Rodriguez, M.D. (Wake Forest Baptist Health) titled "Interim Results of a Phase I Study of TNB-383B, a BCMAxCD3 T-cell Redirecting Antibody in Relapsed/Refractory Multiple Myeloma". The presentation will summarize interim data from 58 patients receiving escalating doses from 0.025 mg – 60 mg. Since the study is still ongoing, 81% of responders continue on treatment. Early results show an improved safety and efficacy profile.
"We are very pleased with the clinical data described in this presentation. It is encouraging to see the clinical benefit driven by T-cell mediated tumor lysis without the accompanying safety signals related to cytokine release that are typically associated with immune-activating therapies. The dosing schedule of once every three weeks allows for reduced clinic visits compared to other BCMAxCD3 bispecifics in development. Overall, we are excited to see the unique attributes of Teneobio’s CD3-engager platform validated in the clinic. We look forward to continued development of TNB-383B as well other bi-specific antibodies in our pipeline," said Ben Buelow, M.D., Ph.D., Chief Medical Officer of Teneobio.